Thyroid cancer is the most common endocrine malignancy and ranks as the fifth most common cancer diagnosed in women. Rising incidence of thyroid cancer is reflected by the projected 60,000 new cases in 2013. A majority of patients have differentiated thyroid cancer and are managed successfully with a combination of surgery and radioiodine (RAI) therapy. However, tumors may present or recur as RAI-refractory or metastatic, in which case they have a poorer prognosis and death is common. Anaplastic thyroid cancer, although rare, is typically unresectable at presentation, highly resistant to therapy, uniformly RAI-resistant, and associated with a median survival of less than one year. Approximately 2,000 patients with recurrent or advanced thyroid cancer die each year in the U.S. and many others suffer from progressive, symptomatic disease. More detailed understanding of the pathways involved, and novel targeted therapies are thus desperately needed for patients with advanced thyroid cancer. Numerous clinical data have recently pointed to the PI3K/PTEN/AKT pathway as a crucial player in both differentiated and anaplastic thyroid cancer. During the previous granting cycle, using genetically defined mouse models, we have demonstrated that constitutive activation of PI3K signaling predisposes to the development of metastatic thyroid cancer, that it cooperates with relevant additional relevant genetic alterations to induce poorly differentiated and anaplastic thyroid tumors, and that these advanced tumors display rapid adaptive resistance to PI3K inhibition. Furthermore, our preliminary data suggest the existence of PI3K-dependent, AKT-independent pathways essential for thyroid transformation. The current application has two broad, long-term objectives. The first goal is to utilize a combination of in vivo, ex vivo, and in vitro approaches to further dissect the early stages of thyroid tumorigenesis and identify key signaling nodes required for thyrocyte transformation and essential for maintenance of established tumors, which may provide novel therapeutic opportunities. The second objective is to characterize in vivo the cell autonomous and non-autonomous mechanisms through which PI3K-active thyroid tumor cells develop adaptive resistance to PI3K inhibitors, and to test the efficacy of combination therapies targeting key mediators of resistance.

Public Health Relevance

Approximately 2,000 patients with thyroid cancer die each year in the U.S., and many more suffer from progressive, symptomatic disease. The limited number of advanced thyroid cancer patients has been a major obstacle to our understanding of the molecular mechanisms involved in disease progression, as well as to the development of effective therapies. Furthermore, even when the driving oncogenic insults are known and targeted inhibitors are available, cancers invariably develop resistance to them. In this application, we leverage the power of mouse genetics and in vivo disease modeling to characterize novel pathways that are critical for thyroid cancer development and to define the mechanisms involved in establishing resistance to targeted therapies. Successful completion of the proposed studies will help design effective therapies to overcome resistance, and will provide benefit not only to advanced thyroid cancer patients, but also to those with other tumor types sharing the same genetic alterations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA128943-11
Application #
9600605
Study Section
Molecular and Cellular Endocrinology Study Section (MCE)
Program Officer
Yassin, Rihab R
Project Start
2007-07-01
Project End
2019-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine, Inc
Department
Type
DUNS #
079783367
City
Bronx
State
NY
Country
United States
Zip Code
10461
De Martino, Daniela; Yilmaz, Emrullah; Orlacchio, Arturo et al. (2018) PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett 439:56-65
Orlacchio, Arturo; Ranieri, Michela; Brave, Martina et al. (2017) SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance. Cancer Res 77:6914-6926
Di Cristofano, Antonio (2017) SGK1: The Dark Side of PI3K Signaling. Curr Top Dev Biol 123:49-71
Champa, Devora; Orlacchio, Arturo; Patel, Bindi et al. (2016) Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget 7:34453-71
Mio, Catia; Lavarone, Elisa; Conzatti, Ketty et al. (2016) MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer 23:335-47
Champa, Devora; Di Cristofano, Antonio (2015) Modeling anaplastic thyroid carcinoma in the mouse. Horm Cancer 6:37-44
Champa, Devora; Russo, Marika A; Liao, Xiao-Hui et al. (2014) Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocr Relat Cancer 21:755-67
Russo, Marika A; Kang, Kristy S; Di Cristofano, Antonio (2013) The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations. Thyroid 23:1284-93
Di Cristofano, Antonio (2013) Obesity and thyroid cancer: is leptin the (only) link? Endocrinology 154:2567-9
Sponziello, Marialuisa; Lavarone, Elisa; Pegolo, Enrico et al. (2013) Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology 154:3043-53

Showing the most recent 10 out of 17 publications